BELLICUM PHARMACEUTICALS, INC 4

Accession 0001209191-14-077760

CIK 0001358403operating

Filed

Dec 22, 7:00 PM ET

Accepted

Dec 23, 4:30 PM ET

Size

23.2 KB

Accession

0001209191-14-077760

Form 4

Period: 2014-12-23

Director

Transactions

Conversion
Common Stock
2014-12-23+298,434→ 445,492 total(indirect: By McGuyer Investments Ltd.)
Conversion
Common Stock
2014-12-23+1,227,132→ 1,672,624 total(indirect: By McGuyer Investments Ltd.)
Conversion
Common Stock
2014-12-23+301,842→ 1,974,466 total(indirect: By McGuyer Investments Ltd.)
Conversion
Common Stock
2014-12-23+196,197→ 2,170,663 total(indirect: By McGuyer Investments Ltd.)
Other
Common Stock
2014-12-23+44,735→ 2,215,398 total(indirect: By McGuyer Investments Ltd.)
Conversion
Series A Convertible Preferred Stock
2014-12-23−507,339→ 0 total(indirect: By McGuyer Investments Ltd.)
→ Common Stock (298,434 underlying)
Conversion
Series B Convertible Preferred Stock
2014-12-23−2,086,125→ 0 total(indirect: By McGuyer Investments Ltd.)
→ Common Stock (1,227,132 underlying)
Conversion
Series C Convertible Preferred Stock
2014-12-23−513,133→ 0 total(indirect: By McGuyer Investments Ltd.)
→ Common Stock (301,842 underlying)
Conversion
Series C Convertible Preferred Stock
2014-12-23−333,536→ 0 total(indirect: By McGuyer Investments Ltd.)
→ Common Stock (196,197 underlying)

Footnotes (6)

[F1]The Reporting Person has voting and investment power held by McGuyer Investments Ltd. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
[F2]Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.
[F3]The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
[F4]The Series B Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
[F5]The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
[F6]On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.

Documents

1 file

BELLICUM PHARMACEUTICALS, INC

CIK 0001358403

Entity typeoperating